In 1999 Xinetix was contracted to assist the Newport R&D team in completing development of the Model e300 critical care ventilator that had been in development for more than four years. Following launch of the e300, Hal Walbrink joined the management team to orchestrate a financial turn around on this wholly owned division of a Janapnese company.
Xinetix provided project leadership leading to e300 product launch in under one year.
Hal Walbrink accepted an interim executive management position as Executive Vice President, General Manager, and Chief Operating Officer to manage the company back to profitability.
The company went from a loss of $200k per month to turning a profit of $1 million per month within 18 months. This was accomplished through launch of the e300, internal process improvements, manpower reorganization, and product line additions. In 2000 Hal negotiated the purchase of the HT50 ventilator from Flight Medical in Israel.